Over the past three years, LAV.311 has consistently demonstrated control of fruit rot and powdery mildew in grapes, strawberries, cucurbits and fruiting vegetables, in more than 30 state trials. -United, Europe and Israel. LAV.311 is based on a new naturally occurring bacterium, which was selected by the Evogene team MicroBoost AI. This allows flexibility of use and integration of the product into custom and existing fungicide application programs. In addition, it responds to an integrated pest management approach (IPM), reduced use of synthetic chemistry, based on more durable materials.
Commented Gouri OronCEO of Organic Lavie: “We are delighted to have reached this key product milestone and are targeting the 2024 growing season for the commercial launch of this product. We have high expectations for our unique biofungicide offering and this is a big step towards commercialization.
Mr. Haviv offerPresident of Organic Lavie and President and CEO of Evogenesaid, “I am delighted to see the tremendous progress that continues to be made within Lavie Bio’s product pipeline. Thrivus™our bio-inoculant, was marketed earlier this year, and LAV.311, our bio-fungicide has now reached the regulatory stage. Lavie Bio’s The product pipeline presents a valuable opportunity to implement sustainable agricultural practices in harmony with nature, using microbes already present in the environment. Recent advances in our pipeline to the pre-commercial and commercial stages demonstrate the power and unique capabilities of Lavie Bio’s technology platform.”
About Lavie Bio’s Product LAV.311
LAV.311 is a water dispersible granulate (WDG) based on Pseudomonas beetle. This strain has multiple modes of action, combining preventive, competitive and plant-induced resistance modes of action against fruit rot and leaf diseases.
About Lavie Bio Ltée.
Organic Laviea subsidiary of Evogene Ltd., aims to improve food quality, sustainability and agricultural productivity through the introduction of microbiome-based agrobiologics. Organic Lavie uses a proprietary predictive computing platform, the BDD Platform, harnessing the power of big data and advanced computing, for the discovery, optimization and development of bio-stimulants and bio-pesticides products.
For more information, please visit www.lavie-bio.com.
About Evogene Ltd. :
Evogen (Nasdaq: EVGN, TASE: EVGN) is a computational biology company that aims to revolutionize life science-based product development by using advanced technologies to increase the likelihood of success while reducing development time and cost. Evogene has established three unique technology engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging big data and artificial intelligence and incorporating a deep multidisciplinary understanding of life sciences. Each technology engine is focused on the discovery and development of products based on one of the following building blocks: microbes (MicroBoost AI), small molecules (ChemPass AI) and genetics (GeneRator AI). Evogene uses its technology engines to develop products through subsidiaries and with strategic partners. Currently, major Evogene subsidiaries are using the technology drivers to develop human microbiome-based therapies by Biomica Ltd., medical cannabis products by Canonic Ltd., agricultural chemicals by AgPlenus Ltd. and agricultural organic products by Lavie Bio Ltd.
This press release contains “forward-looking statements” relating to future events. These statements can be identified by words such as “may”, “could”, “expect”, “intend”, “anticipate”, “plan”, “believe”, “planned”, ” esteem” or words of similar meaning. For instance, Organic Lavie and Evogene use forward-looking statements in this press release when discussing the results of LAV.311’s registration process, annual U.S. crop protection chemical fungicide expenditures, timing of commercial launch of LAV. .311, the success of LAV.311 with the control of fruit rot and powdery mildew and Lavie Bio’s product pipeline. These statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties that are difficult to predict, and are not guarantees of future performance. Accordingly, the actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including without limitation the risk factors contained in Evogene’s reports filed with applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or undertaking to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections.
THE SOURCE Organic Lavie